Key finding
HbA1c level was significantly lower with sitagliptin than with conventional therapy (6.56% ± 0.05% versus 6.72% ± 0.05%, p = 0.008)
This study evaluated the effects of sitagliptin on carotid intima-media thickness in type 2 diabetes patients. It found no significant change in IMT but a notable reduction in HbA1c levels.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Quick read
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Sitagliptin
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Primary outcome
Common carotid artery intima-media thickness (IMT)
Comparator
Conventional therapy group
Plain-language summary
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the effects of sitagliptin on carotid intima-media thickness in type 2 diabetes patients. It found no significant change in IMT but a notable reduction in HbA1c levels.
The findings suggest that while sitagliptin can effectively lower HbA1c levels in patients with type 2 diabetes, it does not appear to influence carotid intima-media thickness, a marker of cardiovascular risk. This is important for clinicians to consider when managing diabetes and assessing cardiovascular health in their patients.
The study design was non-randomized, which may affect the reliability of the results. The sample size and demographic characteristics may limit generalizability. Only short-term outcomes were evaluated, leaving long-term effects uncertain.
Published in
Publication details and source links for this paper.
Jun-ichi O, Toyoaki M, Masafumi K, et al. Effects of Sitagliptin Added to Conventional Therapy on Carotid Intima-Media Thickness in Type 2 Diabetes: A Randomized Trial. PLOS Medicine. 2016;13(6):e1002051. doi:10.1371/journal.pmed.1002051
Save this study and add notes to your research library.
Sitagliptin did not significantly change common carotid artery IMT (mean difference −0.009 mm, p = 0.309).
HbA1c levels were significantly lower with sitagliptin compared to conventional therapy (6.56% vs. 6.72%, p = 0.008).
Serious hypoglycemia episodes were recorded only in the conventional therapy group.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Sitagliptin and Common carotid artery intima-media thickness (IMT), Episodes of serious hypoglycemia, HbA1c.
This study contributes evidence to
Primary intervention
Sitagliptin
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
3
Evidence pairs
172
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Core evidence
The primary outcomes reported in this study.
Sitagliptin → Common carotid artery intima-media thickness (IMT)
Sitagliptin → Common carotid artery intima-media thickness (IMT)
Evidence profile
Sitagliptin → Episodes of serious hypoglycemia
Sitagliptin → Episodes of serious hypoglycemia
Evidence profile
Sitagliptin → HbA1c
Sitagliptin → HbA1c
Evidence profile
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on DPP-4 Inhibitors and HbA1c.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
Jump to pre-filtered views in the evidence archive.
Generated from the study's connected evidence using Evidence Intelligence™.
DPP-4 Inhibitors appears to improve HbA1c.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 57.7 | strong positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 7 supporting studies with consistent results and a positive effect signal.
Limitations
Current evidence does not show a clear benefit of Sitagliptin for Common carotid artery intima-media thickness (IMT).
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Common carotid artery intima-media thickness (IMT)
EvidenceScore™ Limited | EvidenceScore™ 38.1 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Sitagliptin for Episodes of serious hypoglycemia.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Episodes of serious hypoglycemia
EvidenceScore™ Limited | EvidenceScore™ 38.1 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, archive views, and research summaries.
Follow the topics this study contributes to.
Open broader archive views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
